Genotype 4 and the global challenge of hepatitis C treatment

Affiliations

¹ NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK.
² Institute of Clinical Trials and Methodology, University College London, London, UK; Kirby Institute, University of New South Wales, NSW, Australia.
³ Imperial College London, London W2 1NY, UK. Electronic address: g.cooke@imperial.ac.uk.

Free article

Comment

Stephen Ryder et al. Lancet Gastroenterol Hepatol. 2016 Sep.

Free article

. 2016 Sep;1(1):3-4.

doi: 10.1016/S2468-1253(16)30006-1. Epub 2016 Jun 16.

¹ NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK.
² Institute of Clinical Trials and Methodology, University College London, London, UK; Kirby Institute, University of New South Wales, NSW, Australia.
³ Imperial College London, London W2 1NY, UK. Electronic address: g.cooke@imperial.ac.uk.

No abstract available

Comment on

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Asselah T, et al. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):25-35. doi: 10.1016/S2468-1253(16)30001-2. Epub 2016 Jun 16. Lancet Gastroenterol Hepatol. 2016. PMID: 28404108 Clinical Trial.
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Waked I, et al. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):36-44. doi: 10.1016/S2468-1253(16)30002-4. Epub 2016 Jun 16. Lancet Gastroenterol Hepatol. 2016. PMID: 28404110 Clinical Trial.